# Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

> **NCT01260350** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 292 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** SOF
- **DRUG:** RBV
- **DRUG:** PEG
- **DRUG:** LDV
- **DRUG:** GS-9669
- **DRUG:** LDV/SOF

## Key facts

- **NCT ID:** NCT01260350
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-10
- **Final completion:** 2013-12
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2014-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260350, "Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01260350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*